Change - Announcement of Cessation::Cessation of Dr He JuBin as Chief Executive Officer
Issuer & Securities
CHINA MEDICAL (INTERNATIONAL) GROUP LIMITED
CHINA MED (INTL) W201029 - SG5FF2000003 - 1F6W
CHINA MEDICAL (INTL) GROUP LTD - SG1T21929867 - 5IB
CHINA MED (INTL) W180329 - SG9QB8991245 - 5VNW
Change - Announcement of Cessation
Date &Time of Broadcast
Announcement Sub Title
Cessation of Dr He JuBin as Chief Executive Officer
Submitted By (Co./ Ind. Name)
Tan Swee Gek
Description (Please provide a detailed description of the event in the box below)
The number of cessations of appointments specified in Rule 704(6) of the Listing Manual over the past 12 months does not take into account the Cessation.
This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the Sponsor) for compliance with the Singapore Exchange Securities Trading Limited (the SGX-ST) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.
This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.
The contact person for the Sponsor is Lance Tan, Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: firstname.lastname@example.org).
Name Of Person
Is effective date of cessation known?
If yes, please provide the date
Detailed Reason (s) for cessation
Dr He has tendered his resignation as Chief Executive Officer of China Medical (International) Group Limited on 11 December 2017 and his resignation will take effect from 11 December 2017. He will be seeking new opportunities for his own personal development plans.
Based on its enquiries, the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. is satisfied that, other than as disclosed in this announcement, there are no other material reasons for the cessation of Dr He JuBin as the Chief Executive Officer of the Company.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
Any other relevant information to be provided to shareholders of the listed issuer?
Date of Appointment to current position
Does the AC have a minimum of 3 members (taking into account this cessation)?
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Executive Officer
Role and responsibilities
Executive. Dr He is responsible for the Group's medical and healthcare business operations and profitability and the Group's compliance with regulations and laws in the People's Republic of China.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Shareholding interest in the listed issuer and its subsidiaries?
Past (for the last 5 years)
March 2014 - November 2014
Director, Beijing Prometheus Biomedics Co., Ltd.
July 2014 - June 2015
Director, Prometheus Biomedics (Hong Kong) Ltd.